iBio (IBIO) Moat Score: 2/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBIO iBio Inc IBIO
30 GF Score
Price $1.44
GF Value $0.05
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is iBio Moat Score?

iBio IBIO -1.04% 30 Moat Score is 2 as of Jul. 16, 2026. GuruFocus rates IBIO with a GF Score™ of 30/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, iBio ranks better than 58.31% on this metric.

iBio has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

iBio has No Moat: iBio Inc has very weak competitive advantages with limited market share and brand recognition. Its intellectual property is not strong enough to provide a sustainable competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes iBio might have No Moat - Very weak/transient advantages.

iBio  (NAS:IBIO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

iBio Moat Score Related Terms

IBIO vs RNTX, RANI, OSTX: Moat Score Comparison

For the Biotechnology subindustry, iBio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iBio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iBio's Moat Score distribution charts can be found below:

* The bar in red indicates where iBio's Moat Score falls into.


IBIO
30GF Score
iBio Inc IBIO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
iBio (IBIO) has a Moat Score of 2 as of Jul. 16, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, iBio ranks #582 out of 1396 companies in the Biotechnology industry, placing it in the top 41.7%.
Is iBio's Moat Score too high?
iBio's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. iBio's value of 2 is 0% at this industry median. Based on the distribution chart, iBio ranks #582 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint. Overall, iBio has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iBio's Moat Score compare to RNTX and RANI?
According to the Biotechnology industry distribution chart, iBio ranks #582 out of 1396 companies for Moat Score. This puts iBio in the upper half of its industry. The industry median Moat Score is 2.00. iBio's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iBio's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iBio's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iBio stock overvalued right now?
Based on GuruFocus' analysis, iBio (IBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $1.44 — trading 2770% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. iBio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For iBio (IBIO), the current Moat Score is 2 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iBio (IBIO) Overvalued in 2026?

Based on GuruFocus' analysis, iBio stock appears to be overvalued. The current stock price of $1.44 is trading 2770% above its estimated GF Value™ of $0.05. GuruFocus considers iBio to be Significantly Overvalued.

Key valuation signals for IBIO:

  • Moat Score: 2
  • GF Value™: $0.05 vs. price of $1.44 (2770% above fair value)
  • GF Score™: 30/100 with 2 warning signs
  • Industry Position: 0% at the Biotechnology median (#582 of 1396)

No single metric tells the full story. See the IBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iBio Business Description

Other Exchanges 0JV0:Germany
Address 11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
30GF Score

Get the complete analysis for IBIO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44
Price
$0.05
GF Value